India, in order to climb the intellectual property and innovation indexes, has to strike the right balance between providing public health to all and, at the same time,
Arguments over the term of the patents granted are at the heart of the Copaxone conflict, says Archana Shanker. Copaxone (glatiramer acetate) is a blockbuster drug for the
April 2014 marks the first anniversary of the judgment of the Indian Supreme Court in the Novartis case, wherein the decision of the Indian Patent Office refusing grant
A discussion by Safir Anand on the laws and codes of practices governing advertising of medicinal products in India. In India, pharmaceutical advertising is governed by The Drugs
Patients everywhere would benefit from top-down reform to align India’s patent law with global norms say Pravin Anand and Archana Shanker. To protect the IP of innovators and
Archana Shanker and Devinder Singh Rawat discuss the rise and regulation of biosimilar biologics in the Indian pharmaceutical market. Biologics are an important component of the pharmaceutical industry and
Pravin Anand and Neeti Wilson look at the workings of intellectual property rights in the life sciences industry. An in-depth look into the interaction between intellectual property rights
